Connect
MJA
MJA

Respiratory symptoms and illness in older Australians: the Burden of Obstructive Lung Disease (BOLD) study

Brett G Toelle, Wei Xuan, Tessa E Bird, Michael J Abramson, David N Atkinson, Deborah L Burton, Alan L James, Christine R Jenkins, David P Johns, Graeme P Maguire, A W (Bill) Musk, E Haydn Walters, Richard Wood-Baker, Michael L Hunter, Bruce J Graham, Phillipa J Southwell, William M Vollmer, A Sonia Buist and Guy B Marks
Med J Aust 2013; 198 (3): 144-148. || doi: 10.5694/mja11.11640

Summary

Objective: To measure the prevalence of chronic obstructive pulmonary disease (COPD) among people aged 40 years or older in Australia.

Design, setting and participants: A cross-sectional study of people in the community aged ≥ 40 years, selected at random using electoral rolls, in six sites chosen to reflect the sociodemographic and geographic diversity of Australia, conducted between 2006 and 2010. Standardised questionnaires were administered by interview. Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio were measured by spirometry, before and after bronchodilator administration.

Main outcome measure: Prevalence of COPD, classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 criteria.

Results: Complete data were available for 1620 men (participation rate, 26%) and 1737 women (participation rate, 28%). The prevalence of GOLD Stage II or higher COPD (defined as post-bronchodilator FEV1/FVC ratio < 0.70 and FEV1 < 80% predicted) was 7.5% (95% CI, 5.7%–9.4%) among people aged ≥ 40 years, and 29.2% (95% CI, 18.1%–40.2%) among those aged ≥ 75 years. Among people aged ≥ 40 years, the prevalence of wheeze in the past 12 months was 30.0% (95% CI, 27.5%–32.5%), and prevalence of shortness of breath when hurrying on the level or climbing a slight hill was 25.2% (95% CI, 22.7%–27.6%).

Conclusions: Symptoms and spirometric evidence of COPD are common among people aged 40 years or older and increase with age. Further research is needed to better understand the diagnosis and management of COPD in Australia, along with continuing efforts to prevent the disease.

  • Brett G Toelle1
  • Wei Xuan1
  • Tessa E Bird1
  • Michael J Abramson2
  • David N Atkinson3,4
  • Deborah L Burton5
  • Alan L James6
  • Christine R Jenkins7
  • David P Johns8
  • Graeme P Maguire9,10
  • A W (Bill) Musk11,12
  • E Haydn Walters8
  • Richard Wood-Baker8
  • Michael L Hunter11
  • Bruce J Graham13
  • Phillipa J Southwell5
  • William M Vollmer14
  • A Sonia Buist15
  • Guy B Marks1

  • 1 Department of Respiratory and Environmental Epidemiology, Woolcock Institute of Medical Research, Sydney, NSW.
  • 2 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC.
  • 3 Rural Clinical School of WA, University of Western Australia, Broome, WA.
  • 4 Kimberley Aboriginal Medical Services Council, Broome, WA.
  • 5 School of Biomedical Sciences, Charles Sturt University, Orange, NSW.
  • 6 Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Perth, WA.
  • 7 Department of Thoracic Medicine, Woolcock Institute of Medical Research, Sydney, NSW.
  • 8 School of Medicine, University of Tasmania, Hobart, TAS.
  • 9 Baker IDI Central Australia, Alice Springs, NT.
  • 10 Cairns Clinical School, James Cook University, Cairns, QLD.
  • 11 Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA.
  • 12 School of Population Health, University of Western Australia, Perth, WA.
  • 13 School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW.
  • 14 Center for Health Research Northwest, Kaiser Permanente Northwest, Portland, Ore, USA.
  • 15 Division of Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland, Ore, USA.


Acknowledgements: 

We thank the research staff at each of the study sites for recruiting and testing participants: Busselton: Elspeth Inglis, Peta Grayson; Broome: David Reeve, Matthew Yap, Mary Lane, Wendy Cavilla; Melbourne: Angela Lewis, Joan Raven, Joan Green; Rural New South Wales: Melanie Heine, Cassanne Eccleston, Julie Cooke, Brian Spurrell, Robyn Paton; Sydney: Kate Hardaker, Paola Espinel; Tasmania: Carol Phillips. Funding sources for the Australian clinical centres include the National Health and Medical Research Council, Australian Lung Foundation, Air Liquide, AstraZeneca, GlaxoSmithKline and Boehringer Ingelheim.

Competing interests:

William Vollmer and Sonia Buist served as Directors of the BOLD Operations Center, which received funding in the form of unrestricted educational grants from Boehringer Ingelheim, Pfizer, ALTANA, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi, and Merck. Guy Marks, Michael Abramson and Christine Jenkins served on advisory committees for the BOLD Operations Center.

  • 1. McKenzie DK, Abramson M, Crockett AJ, et al. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Brisbane: Australian Lung Foundation and Thoracic Society of Australia and New Zealand, 2010.
  • 2. Abramson MJ, Crockett AJ, Frith PA, McDonald CF. COPDX: an update of guidelines for the management of chronic obstructive pulmonary disease with a review of recent evidence. Med J Aust 2006; 184: 342-345. <MJA full text>
  • 3. Australian Institute of Health and Welfare. Chronic respiratory diseases in Australia: their prevalence, consequences and prevention. Canberra: AIHW, 2005. (AIHW Cat. No. PHE 63.) http://www.aihw.gov.au/publication-detail/?id=6442467751 (accessed Nov 2012).
  • 4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2010. http://www.goldcopd.org/Guidelines/guideline-2010-gold-report.html (accessed Dec 2011).
  • 5. Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia. Canberra: AIHW, 2010. (AIHW Cat. No. ACM 20.) http://www.aihw.gov.au/publication-detail/?id=6442468361 (accessed Nov 2012).
  • 6. Begg S, Vos T, Barker B, et al. The burden of disease and injury in Australia 2003. Canberra: AIHW, 2007. (AIHW Cat. No. PHE 82.) http://www.aihw.gov.au/publication-detail/?id=6442467990 (accessed Nov 2012).
  • 7. Abramson MJ. Respiratory symptoms and lung function in older people with asthma or chronic obstructive pulmonary disease. Med J Aust 2005; 183 (1 Suppl): S23-S25.
  • 8. Wilson D, Adams R, Appleton S, Ruffin R. Difficulties identifying and targeting COPD and population-attributable risk of smoking for COPD: a population study. Chest 2005; 128: 2035-2042.
  • 9. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 2004; 9: 458-465.
  • 10. Caramori G, Bettoncelli G, Tosatto R, et al. Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy. Monaldi Arch Chest Dis 2005; 63: 6-12.
  • 11. Matheson MC, Abeysena C, Raven JM, et al. How have we been managing chronic obstructive pulmonary disease in Australia? Intern Med J 2006; 36: 92-99.
  • 12. Taylor AW, Baldock KL, Chittleborough CR, et al. Population surveillance in North West Adelaide: the impact of diagnosed and undiagnosed chronic obstructive pulmonary disease (COPD) on quality of life. Eur Respir J 2005; 26 Suppl 49: 383s.
  • 13. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005; 2: 277-283.
  • 14. Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
  • 15. James AL, Knuiman MW, Divitini ML, et al. Changes in the prevalence of asthma in adults since 1966: the Busselton health study. Eur Respir J 2010; 35: 273-278.
  • 16. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
  • 17. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999; 159: 179-187.
  • 18. Australian Bureau of Statistics. Census of population and housing: Socio-Economic Indexes for Areas (SEIFA), Australia — technical paper, 2001. Canberra: ABS, 2004. (ABS Cat. No. 2039.0.55.001.)
  • 19. Australian Bureau of Statistics. Information paper: ABS views on remoteness, 2001. Canberra: ABS, 2001. (ABS Cat. No. 1244.0.)
  • 20. Fletcher CM. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med 1952; 45: 577-584.
  • 21. Miller MR, Quanjer PH, Swanney MP, et al. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011; 139: 52-59.
  • 22. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007; 62: 237-241.
  • 23. Marks GB. Are reference equations for spirometry an appropriate criterion for diagnosing disease and predicting prognosis? Thorax 2012; 67: 85-87. [Epub ahead of print 2011; 8 Aug.]
  • 24. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010; 376: 803-813.
  • 25. Australian Centre for Asthma Monitoring. Asthma in Australia 2008. Canberra: AIHW, 2008. (AIHW Cat. No. ACM 14.)
  • 26. Walters JA, Walters EH, Nelson M, et al. Factors associated with misdiagnosis of COPD in primary care. Prim Care Respir J 2011; 20: 396-402.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.